Congenital heart defects in Adults
Reading File
Finding Sources
Finding Sources
Searching PubMed
"congenital heart disease"[MeSH Terms] AND "adult"[MeSH Terms]
Congenital heart defects in Adults Etiology Epidemiology Pathophysiology Clinical signs and symptoms Diagnosis Differential diagnosis Treatment Complications Prevention
Reading File
Finding Sources
Finding Sources
Searching PubMed
"congenital heart disease" AND "adults" AND management
Reading File
Finding Sources
Reading Article
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content. Let me compile the full, detailed answer.
Congenital Heart Defects in Adults (Adult Congenital Heart Disease - ACHD)
1. Etiology
Congenital heart defects (CHDs) result from abnormal embryological development of cardiac structures. About 20% are associated with a known syndrome or chromosomal anomaly; the remaining ~80% are multifactorial.
Genetic/Chromosomal Causes
| Syndrome | Common CHD |
|---|---|
| Down syndrome (Trisomy 21) | Endocardial cushion defects, VSD (~50% of patients) |
| Trisomy 13 and 18 | VSD (~90% of patients) |
| Turner syndrome (45,X) | Aortic coarctation, aortic stenosis, ASD |
| DiGeorge / CATCH-22 (22q11 deletion) | Tetralogy of Fallot, truncus arteriosus, interrupted aortic arch |
| Marfan syndrome (FBN1) | Aortic root dilation, mitral valve prolapse |
| Noonan syndrome | Pulmonary stenosis, HCM |
| Williams syndrome (7q11 deletion) | Supravalvular aortic stenosis, peripheral pulmonary stenosis |
About 15% of Tetralogy of Fallot patients carry a 22q11 deletion; prevalence is higher with a right aortic arch.
Non-Genetic / Teratogenic Causes
- Maternal infections: Rubella (PDA, pulmonary artery stenosis), CMV, Coxsackievirus
- Maternal medications: Thalidomide, lithium (Ebstein anomaly), valproic acid, retinoic acid, phenytoin
- Maternal conditions: Diabetes mellitus (VSD, TGA, HCM), systemic lupus erythematosus (heart block), phenylketonuria, alcohol use (FAS - VSD, ASD)
- Environmental: Radiation exposure, organic solvents
"About 20% of congenital heart defects are associated with a syndrome or chromosomal anomaly." - Goldman-Cecil Medicine
2. Epidemiology
- CHDs are diagnosed in approximately 1% of live births in the United States
- Prevalence in adults: 3-4 per 1,000 adults
- An estimated 2.4 million people in the United States currently live with CHD - two-thirds are adults, a dramatic shift from prior decades when most patients died in childhood
- Approximately 300,000 Americans have severe CHD (defined as two or more abnormalities, typically with cyanosis at birth)
- Advances in surgical and medical therapy have pushed the median age of patients with severe lesions from childhood into late adolescence and adulthood
Relative Prevalence of Specific Lesions in Adults
| Lesion | Prevalence |
|---|---|
| Bicuspid aortic valve | ~2% of the general population; most common adult CHD; up to 50% of surgical aortic stenosis cases |
| Atrial septal defect (ASD) | 30-40% of CHD in adults; ostium secundum accounts for 7% of all congenital lesions |
| Ventricular septal defect (VSD) | 15-20% of all congenital lesions (high spontaneous closure rate explains lower adult prevalence) |
| Patent ductus arteriosus (PDA) | 5-10% of all congenital cardiac lesions |
| Pulmonary stenosis / Coarctation of aorta | 3-10% each |
| Tetralogy of Fallot | Most common cyanotic CHD in adults |
| Complex lesions (tricuspid atresia, Ebstein anomaly, TGA, univentricular heart) | ≤2.5% of all CHD |
Goldman-Cecil Medicine, p. 604
3. Pathophysiology
CHDs are classified hemodynamically into three major groups:
A. Left-to-Right Shunts (Acyanotic)
- Abnormal communication allows oxygenated left-sided blood to enter the pulmonary circulation
- Examples: ASD, VSD, PDA, atrioventricular septal defect (AVSD)
- Increased pulmonary blood flow and pressure → right ventricular hypertrophy → right-sided heart failure
- With time, elevated pulmonary vascular resistance can cause shunt reversal (right-to-left), producing late-onset cyanosis (Eisenmenger syndrome)
- Cyanosis is NOT an early feature; it signals irreversible pulmonary vascular disease
B. Right-to-Left Shunts (Cyanotic)
- Deoxygenated blood bypasses the pulmonary circulation and enters the systemic arterial system
- Examples: Tetralogy of Fallot, transposition of great arteries (TGA), truncus arteriosus, tricuspid atresia
- Results in: cyanosis, clubbing, polycythemia, hyperviscosity
C. Obstructive Lesions
- Narrowing of chambers, valves, or great vessels obstructs flow
- Examples: Pulmonary stenosis, aortic stenosis (including bicuspid AV), coarctation of the aorta
- Leads to pressure overload, ventricular hypertrophy, and eventually failure
Eisenmenger Syndrome
A critical endpoint where a large left-to-right shunt (most commonly VSD, ASD, or PDA) leads to progressive pulmonary vascular remodeling, rising pulmonary vascular resistance, shunt reversal to right-to-left, and systemic cyanosis. Once established, this represents irreversible pulmonary vascular obstructive disease and most corrective procedures are contraindicated.
Robbins & Kumar Basic Pathology, p. 347-348
4. Clinical Signs and Symptoms
General Presentation
ACHD patients present in two main ways:
- Previously undiagnosed CHD presenting for the first time in adulthood (often milder lesions like secundum ASD, bicuspid aortic valve, small VSD, PDA)
- Repaired or palliated CHD surviving into adulthood with residual defects, sequelae, or complications
Common Symptoms
- Dyspnea on exertion - most common; reflects reduced cardiac output or elevated pulmonary pressures
- Palpitations / arrhythmias - atrial fibrillation, flutter, supraventricular or ventricular tachycardia
- Fatigue - from reduced cardiac reserve
- Cyanosis - central (mucous membranes, tongue), right-to-left shunts
- Syncope / presyncope - outflow obstruction or arrhythmia
- Chest pain - coarctation, aortic stenosis, coronary anomalies
- Stroke / TIA - paradoxical embolism through PFO or ASD, atrial arrhythmias
- Leg fatigue / claudication - coarctation of the aorta
- Hemoptysis - Eisenmenger syndrome, pulmonary AVMs (Hereditary Hemorrhagic Telangiectasia)
Key Physical Signs by Lesion
ASD:
- Wide, fixed splitting of S2 (hallmark) - pathognomonic
- Systolic ejection murmur at pulmonary area (increased flow)
- With large shunt: right ventricular heave
- With pulmonary hypertension: loud P2, tricuspid regurgitation murmur
VSD:
- Holosystolic murmur at left lower sternal border
- With large shunt: displaced apex, S3, signs of left ventricular failure
PDA:
- Continuous "machinery" murmur at left upper sternal border/infraclavicular area
- Wide pulse pressure, bounding pulses
- With Eisenmenger: differential cyanosis (lower extremities more cyanosed than upper)
Tetralogy of Fallot (repaired):
- Pulmonary regurgitation murmur (most common residual)
- Right ventricular heave
- Tet spells (hypercyanotic) less common in adults
Coarctation of the Aorta:
- Upper extremity hypertension with weak/absent femoral pulses
- Blood pressure differential: arms > legs (>20 mmHg)
- Systolic murmur over the posterior mid-thoracic region
- "3 sign" on chest X-ray (notched aorta)
- Bilateral rib notching (posterior 3rd-8th ribs from collateral flow)
- Tortuous ("corkscrew") retinal arteries
- Left ventricular hypertrophy on ECG
Ebstein Anomaly:
- Apically displaced tricuspid valve
- Right-sided cardiomegaly ("box-shaped heart" on CXR)
- Right bundle branch block, Wolff-Parkinson-White pattern on ECG
Eisenmenger Syndrome:
- Central cyanosis, clubbing
- Polycythemia with hyperviscosity symptoms (headache, blurred vision, fatigue)
- Signs of pulmonary hypertension: loud P2, right heart failure
5. Diagnosis
ACHD diagnosis is multi-modal and usually requires specialist evaluation at an accredited ACHD center.
History & Physical Examination
- Detailed birth and surgical history
- Prior catheterization and imaging reports
- Current symptom burden and functional class (NYHA classification)
Electrocardiography (ECG)
- Right axis deviation / right bundle branch block: ASD, right heart lesions
- Left ventricular hypertrophy: aortic stenosis, coarctation
- PR prolongation: Ebstein anomaly, AVSDs
- Delta waves (Wolff-Parkinson-White): Ebstein anomaly (up to 20-25%)
- QTc prolongation: post-repair Tetralogy of Fallot (marker for sudden death risk)
Chest X-Ray
- Cardiomegaly, pulmonary vascular markings
- "3 sign" and rib notching: coarctation
- "Boot-shaped heart": Tetralogy of Fallot
- "Box-shaped heart": Ebstein anomaly
- Enlarged pulmonary artery: pulmonary stenosis, Eisenmenger
Echocardiography (Primary Imaging Modality)
- Transthoracic echo (TTE): First-line; evaluates anatomy, shunts (Doppler, bubble contrast), ventricular function, valve lesions, gradients
- Transesophageal echo (TEE): Better for sinus venosus ASD, PFO, complex anatomy
- Bubble contrast echo: Detects right-to-left shunting (PFO, ASD)
- Estimation of pulmonary artery pressures, shunt size (Qp:Qs ratio)
Cardiac MRI (Gold Standard for Many Lesions)
- Best modality for:
- Visualizing aortic anatomy (coarctation, aneurysms)
- Right ventricular volumes and function (e.g., post-Tetralogy repair)
- Quantifying pulmonary regurgitation
- Complex anatomy not well-seen by echo
- Provides accurate flow quantification and tissue characterization
CT Angiography
- Useful for coronary anatomy, vascular anomalies, and pre-procedural planning
- Alternative when MRI is contraindicated
Cardiac Catheterization
- Hemodynamic assessment: Pulmonary artery pressures, pulmonary vascular resistance (PVR), Qp:Qs ratio
- Vasoreactivity testing: In pulmonary hypertension to assess operability
- Required before surgical correction when pulmonary hypertension is suspected
- Diagnostic and therapeutic (transcatheter closure, stenting)
Exercise Testing
- Assess functional capacity and identify exercise-induced arrhythmias
- Important for risk stratification and sports participation guidance
Holter / Event Monitoring
- For arrhythmia detection in symptomatic patients and those with high arrhythmia risk
Lab Work
- CBC: Polycythemia in cyanotic CHD (compensatory)
- BNP/NT-proBNP: Heart failure monitoring
- Iron studies: Iron-deficiency anemia in cyanotic CHD (blunts adaptive polycythemia)
- Coagulation studies: Bleeding risk in Eisenmenger
6. Differential Diagnosis
ACHD must be distinguished from acquired cardiac conditions, and specific lesions from each other:
| Presenting Feature | CHD to Consider | Acquired Differential |
|---|---|---|
| Dyspnea, right heart failure | ASD, Eisenmenger, Ebstein | COPD, pulmonary embolism, idiopathic PAH, RV cardiomyopathy |
| Systolic murmur, left sternal border | VSD, pulmonary stenosis | Innocent murmur, HCM, aortic stenosis |
| Continuous murmur | PDA, coronary AV fistula, ruptured sinus of Valsalva | Venous hum, mammary souffle (pregnancy), aortic stenosis + regurgitation |
| Central cyanosis + clubbing | Tetralogy of Fallot, Eisenmenger, TGA | Severe COPD/emphysema, pulmonary AVM, methemoglobinemia |
| Upper extremity hypertension (young) | Coarctation of the aorta | Essential hypertension, renovascular hypertension, endocrine HTN |
| Stroke in young adult | PFO with paradoxical embolism | Carotid dissection, hypercoagulable state, atrial fibrillation |
| Wide fixed split S2 | ASD | Normal split S2 (widens on inspiration), RBBB |
| Systolic ejection murmur, elderly | Bicuspid aortic valve with stenosis | Calcific tricuspid aortic stenosis, HOCM, pulmonary flow murmur |
| Right bundle branch block + wide QRS | Ebstein anomaly, post-repair Tetralogy | Acquired RBBB, arrhythmogenic RV cardiomyopathy |
7. Treatment
Management of ACHD requires a multidisciplinary team at a specialized ACHD center (Class I recommendation, 2025 ACC/AHA Guideline).
A. Medical Management
Heart Failure:
- Standard HF therapy (ACE inhibitors/ARBs, beta-blockers, diuretics) for systemic LV dysfunction
- Caution in right-dominant or single-ventricle physiology - standard HF drugs may not apply uniformly
Pulmonary Arterial Hypertension:
- Eisenmenger syndrome: Endothelin receptor antagonists (bosentan - approved specifically for Eisenmenger), phosphodiesterase-5 inhibitors (sildenafil), prostacyclin analogues
- These improve functional class and exercise capacity but do not cure the underlying anatomy
Arrhythmia:
- Anti-arrhythmic drugs (sotalol, amiodarone for atrial arrhythmias)
- Anticoagulation (warfarin or DOACs) for atrial fibrillation and flutter
- Rate control vs. rhythm control individualized to anatomy
Endocarditis Prophylaxis (per 2007 AHA/2020 ESC guidelines):
- Recommended for high-risk lesions:
- Unrepaired cyanotic CHD (including palliative shunts)
- Completely repaired CHD with prosthetic material during the first 6 months post-procedure
- Repaired CHD with residual defects at or adjacent to prosthetic patches/devices
- Cardiac transplant recipients who develop cardiac valvulopathy
- Prophylaxis before dental procedures involving gingival manipulation
Anticoagulation:
- Mechanical prosthetic valves: warfarin (mandatory)
- Fontan circulation: anticoagulation or antiplatelet therapy
- Atrial arrhythmias: individualized
B. Catheter-Based (Interventional) Procedures
Preferred over surgery for many lesions in adults:
| Procedure | Indication |
|---|---|
| Transcatheter ASD/PFO closure (e.g., Amplatzer device) | Hemodynamically significant ASD; PFO with cryptogenic stroke |
| Transcatheter VSD closure | Muscular, traumatic, or residual post-operative VSDs |
| PDA closure (coils/devices) | Significant PDA in adults |
| Balloon/stent for coarctation | Discrete coarctation with peak gradient ≥20 mmHg |
| Pulmonary valve replacement (TPVR - Melody/Sapien valves) | Conduit stenosis/regurgitation post-repair |
| Transcatheter aortic valve (TAVR) | Bicuspid/tricuspid AS, suitable anatomy |
| Catheter ablation | Intra-atrial re-entrant tachycardia (IART), AF, accessory pathways |
Intervention for coarctation is recommended when peak catheterization gradient ≥20 mmHg with systemic hypertension or significant collateral flow on imaging. - Goldman-Cecil Medicine, p. 609
C. Surgical Treatment
Indicated when transcatheter approach is not feasible or lesion complexity requires open surgery:
- Repair of complex anatomy: Sinus venosus ASD (requires patch + anomalous vein rerouting), primum ASD with mitral cleft repair
- Re-operation for residual or recurrent lesions after initial childhood repair
- Tetralogy of Fallot: Pulmonary valve replacement for severe pulmonary regurgitation causing RV dilation/failure
- Fontan revision/conversion for failing Fontan circulation
- Ross procedure / aortic valve replacement: For bicuspid aortic valve disease
- Maze procedure: For refractory atrial arrhythmias at time of cardiac surgery
- Heart/Heart-Lung transplantation: End-stage Eisenmenger syndrome or failing single-ventricle/Fontan (last resort)
D. ICD / Pacemaker Implantation
- ICD for primary prevention of sudden cardiac death in high-risk ACHD (especially repaired Tetralogy of Fallot with QRS >180 ms, severe RV dysfunction, significant arrhythmia burden)
- Pacemaker for complete heart block (post-operative or congenital)
E. Pregnancy Considerations
- ACHD patients planning pregnancy require pre-conception counseling at specialized centers
- High-risk conditions include Eisenmenger syndrome, severe pulmonary hypertension, severe systemic ventricular dysfunction (EF <30%), severe obstructive lesions
- Modified WHO classification guides risk stratification for pregnancy in CHD
8. Complications
Arrhythmias
- Most common long-term complication of ACHD
- Atrial fibrillation and intra-atrial re-entrant tachycardia (IART) are the most frequent, especially after atrial surgery (Mustard, Senning, Fontan procedures)
- Ventricular tachycardia (VT) - risk in repaired Tetralogy of Fallot, especially with wide QRS (>180 ms), significant RV dilation, or LV dysfunction
- Accessory pathways: WPW in Ebstein anomaly (risk of sudden death)
- Complete heart block: post-operative or progressive
Heart Failure
- Occurs due to pressure/volume overload, ventricular dysfunction, valvular regurgitation, or poor surgical outcomes
- Systemic right ventricle (e.g., TGA after Mustard/Senning repair) is particularly prone to failure - RV not designed as systemic ventricle
- Fontan failure: protein-losing enteropathy, plastic bronchitis, hepatic complications
Pulmonary Hypertension / Eisenmenger Syndrome
- Irreversible pulmonary vascular obstructive disease from chronic left-to-right shunts
- Disqualifies patient from most corrective interventions
- Significantly reduced life expectancy
Infective Endocarditis
- Increased risk in patients with prosthetic valves, residual defects, complex CHD, and after procedures
- Predisposing structural lesion + bacteremia = vegetation formation
- CHD is one of the leading underlying conditions for endocarditis in younger patients
Stroke and Systemic Embolism
- Paradoxical embolism through PFO/ASD (especially cryptogenic stroke in patients <55 years)
- Atrial arrhythmias with thrombus formation
- Polycythemia and hyperviscosity in Eisenmenger syndrome → thrombotic events
Aortopathy
- Aortic root/ascending aortic dilation common in bicuspid aortic valve, coarctation, Marfan syndrome, Tetralogy of Fallot, TGA
- Risk of aortic dissection and rupture
Residual and Recurrent Defects
- Residual shunts, valve regurgitation, outflow obstruction after repair
- Re-operations are common in complex CHD
Polycythemia and Hyperviscosity (Cyanotic CHD)
- Secondary erythrocytosis compensates for chronic hypoxia
- Symptoms: headache, blurred vision, fatigue, myalgias
- Risk of both thrombosis AND paradoxical bleeding (thrombocytopenia, platelet dysfunction)
- Phlebotomy reserved for symptomatic hyperviscosity only; indiscriminate phlebotomy is harmful
Sudden Cardiac Death (SCD)
- Leading cause of death in ACHD
- Risk factors: QRS >180 ms (Tetralogy), severe ventricular dysfunction, inducible VT, prior sustained VT/VF, severe outflow obstruction
Hepatic Complications (Fontan)
- Fontan-associated liver disease (FALD): congestive hepatopathy → fibrosis → cirrhosis → hepatocellular carcinoma
Psychosocial Issues
- Anxiety, depression, reduced quality of life
- Transition from pediatric to adult care is a high-risk period for loss to follow-up
9. Prevention
Primary Prevention (Reducing Risk of CHD)
Before Conception:
- Folic acid supplementation (400-800 mcg daily before conception and in first trimester) reduces neural tube defects and may reduce some CHDs
- Optimize pre-existing maternal conditions: diabetes (tight glycemic control periconceptionally), PKU (low-phenylalanine diet), hypothyroidism
- Rubella vaccination of women of childbearing age (prevents congenital rubella syndrome including PDA, pulmonary stenosis)
- Avoid teratogenic medications (especially lithium, thalidomide, valproate, isotretinoin, ACE inhibitors) during pregnancy
During Pregnancy:
- Avoidance of alcohol, smoking, and illicit drugs
- Avoidance of organic solvents and ionizing radiation exposure
- Infectious precautions (avoid exposure to rubella, CMV)
Genetic Counseling:
- Families with known genetic syndromes or prior affected children
- Recurrence risk is ~3-5% if one parent or sibling has CHD; higher with specific single-gene disorders
- Prenatal diagnosis via fetal echocardiography (ideally at 18-22 weeks) for high-risk pregnancies
Secondary Prevention (Preventing Complications in Known CHD)
- Regular follow-up at ACHD centers - lifelong surveillance is mandatory; even repaired CHD is not cured
- Endocarditis prophylaxis in eligible patients (dental hygiene is paramount)
- Anticoagulation in appropriate patients (mechanical valves, AF, Fontan)
- Exercise restrictions individualized to lesion complexity and hemodynamics (2025 ACC/AHA guideline provides specific recommendations by lesion)
- Contraception counseling for women with high-risk CHD
- Avoid phlebotomy unless symptomatic hyperviscosity with Hct >65% in cyanotic patients
- Avoid dehydration in polycythemic/cyanotic patients (increases viscosity and thrombosis risk)
- Occupational guidance: Certain careers (aviation, diving) restricted based on lesion
- Transition planning: Structured transition from pediatric to adult congenital care to prevent gaps in follow-up
Key References
- Goldman-Cecil Medicine, International Edition - Chapter 55: Congenital Heart Disease in Adults (Judith Therrien & Ariane J. Marelli)
- Robbins & Kumar Basic Pathology - Chapter 9: Congenital Heart Disease, p. 347-350
- 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease - Gurvitz et al., J Am Coll Cardiol / Circulation, Feb 2026 [PMID: 41411480] - this is the most current guideline, replacing the 2018 AHA/ACC guideline
Note: The 2025 ACC/AHA guideline published in February 2026 is the current authoritative standard for ACHD management, incorporating evidence from 2017-2024. This supersedes the 2018 guideline. Key updates include revised recommendations on transcatheter interventions, arrhythmia management, and heart failure therapy for complex lesions.
I need different topics seperately under the above Headings
Asking for Preferences
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Here is a complete overview of what was covered:
What Was Covered
9 defects, each given its own full breakdown under all 9 clinical headings, organized into 3 physiological categories:
Category 1 - Left-to-Right Shunts (Acyanotic)
- Atrial Septal Defect (ASD) - including PFO
- Ventricular Septal Defect (VSD)
- Patent Ductus Arteriosus (PDA)
Category 2 - Right-to-Left Shunts (Cyanotic)
- Tetralogy of Fallot (TOF) - both repaired and unrepaired adults
- Eisenmenger Syndrome - as a shared final pathway
- Ebstein Anomaly
Category 3 - Obstructive Lesions
- Bicuspid Aortic Valve / Aortic Stenosis - most common adult CHD
- Pulmonary Stenosis
- Coarctation of the Aorta
Key clinical pearls across all defects:
- Fixed split S2 = ASD (pathognomonic)
- Machinery murmur = PDA
- Differential cyanosis (toes > fingers) = Eisenmenger PDA
- QRS >180 ms = high sudden death risk in repaired TOF
- BP differential arms > legs = Coarctation
- Ejection click not varying with respiration = Bicuspid aortic valve
- Box-shaped heart + RBBB + delta waves = Ebstein anomaly
- The 2025 ACC/AHA Guideline [PMID: 41411480] is the current authoritative standard, published February 2026
Can you concise above
Here is the concise version of all 9 defects under all 9 headings:
CONGENITAL HEART DEFECTS IN ADULTS — CONCISE REFERENCE
CATEGORY 1: LEFT-TO-RIGHT SHUNTS (ACYANOTIC)
1. ATRIAL SEPTAL DEFECT (ASD)
| Heading | Key Points |
|---|---|
| Etiology | Multifactorial; NKX2.5/GATA4/TBX5 gene mutations; Turner syndrome (45,X); Down syndrome. Types: secundum (70%), primum (endocardial cushion defect), sinus venosus (anomalous pulmonary veins), coronary sinus |
| Epidemiology | 30-40% of adult CHD; ostium secundum = 7% of all lesions; female:male 2:1; PFO present in 30% of adults (3x higher in cryptogenic stroke <55 yrs); >70% symptomatic by 5th decade |
| Pathophysiology | L→R shunt → RV volume overload → RV/RA dilation → right heart failure. Pulmonary HTN in 50% of patients >40 yrs; PVOD in 15-20%; Eisenmenger in only 5-10% (isolated secundum ASD) |
| Signs & Symptoms | Dyspnea, fatigue, palpitations (AF/flutter), stroke (paradoxical embolism). Signs: wide fixed split S2 (hallmark), soft pulmonary flow murmur, RV heave, loud P2 (if PAH) |
| Diagnosis | ECG: RBBB, right axis deviation (left axis if primum). CXR: right heart enlargement, dilated PA. Echo/TTE: RV dilation, Doppler shunt. TEE: best for sinus venosus type. MRI: quantifies Qp:Qs, RV volume. Cath: if PAH suspected |
| Differential Dx | Pulmonary stenosis (also split S2 - but not fixed), RBBB, idiopathic PAH, cryptogenic stroke (PFO vs other causes) |
| Treatment | Closure if Qp:Qs ≥1.5:1 with RV dilation or symptoms. Transcatheter (Amplatzer): first-line for secundum. Surgery: sinus venosus, primum (+ mitral repair), large secundum. PFO closure for cryptogenic stroke age 18-60 |
| Complications | AF/flutter (persists even post-closure), right heart failure, PAH/Eisenmenger (5-10%), paradoxical embolism/stroke, mitral valve disease (>50 yrs) |
| Prevention | Folic acid, rubella vaccination. Endocarditis prophylaxis 6 months post-closure. Lifelong surveillance. Genetic counseling (5% recurrence in offspring) |
2. VENTRICULAR SEPTAL DEFECT (VSD)
| Heading | Key Points |
|---|---|
| Etiology | Trisomy 21 (50%), trisomy 13/18 (90%), 22q11 deletion. Types: perimembranous (80%), muscular (highest closure rate), outlet/supracristal (→ AR), inlet (Down syndrome) |
| Epidemiology | 15-20% of all CHD; most common CHD in children. Lower adult prevalence due to high spontaneous closure rate. Large unrepaired VSDs rare in developed countries |
| Pathophysiology | Small: restrictive, minimal hemodynamics, endocarditis risk. Moderate: LV volume overload. Large: equalized LV/RV pressures → massive L→R shunt → progressive PAH → Eisenmenger |
| Signs & Symptoms | Small: loud harsh pansystolic murmur LLSB, otherwise normal ("big noise, small hole"). Large: dyspnea, displaced LV apex, accentuated P2. Eisenmenger: cyanosis, clubbing, murmur disappears |
| Diagnosis | ECG: LAH + LVH (moderate); RVH + right axis (PAH). CXR: shunt vascularity, LA/LV enlargement. Echo: location, size, Qp:Qs, RV pressure. Cath: O2 step-up at RV; PVR if PAH present |
| Differential Dx | Tricuspid regurgitation (pansystolic), MR (apex→axilla), HOCM (dynamic), aortic/pulmonary stenosis (ejection) |
| Treatment | Small: observe, no closure. Moderate-large: closure if Qp:Qs ≥2:1 or LV overload - transcatheter (muscular/perimembranous) or surgical (outlet/inlet). Eisenmenger: closure contraindicated, manage medically |
| Complications | Eisenmenger (large VSD), AR (outlet VSD cusp prolapse), endocarditis, RBBB post-repair (30-65%), complete heart block (<10%), sudden death post-repair (2%), residual shunt (20%) |
| Prevention | Timely neonatal repair before Eisenmenger. Endocarditis prophylaxis 6 months post-prosthetic repair. Regular surveillance |
3. PATENT DUCTUS ARTERIOSUS (PDA)
| Heading | Key Points |
|---|---|
| Etiology | Failure of ductal closure. Causes: prematurity (most common), congenital rubella (classic: PDA + peripheral PS), high altitude, prostaglandin excess. Female 2:1 |
| Epidemiology | 5-10% of CHD; PDA in adults is uncommon (most closed in childhood). Rubella-related PDA now rare with vaccination |
| Pathophysiology | Aorta → PA continuous shunt → LV volume overload. Small: no chamber dilation but endarteritis risk (0.45%/year). Large: dyspnea by 2nd-3rd decade, mortality 3-4%/year by 4th decade. Eisenmenger in ~5%: R→L shunt → differential cyanosis (toes > fingers) |
| Signs & Symptoms | Small: asymptomatic. Moderate/large: dyspnea, exercise intolerance. Signs: continuous "machinery" murmur at 1st-2nd LICS below clavicle, wide pulse pressure, bounding pulses. Eisenmenger: differential cyanosis and clubbing, murmur disappears |
| Diagnosis | ECG: LVH (moderate/large). CXR: dilated aorta + PA, left heart enlargement, calcification at duct (older adults). Echo Doppler: retrograde PA flow. Cath: O2 step-up at PA; PVR measurement |
| Differential Dx | Venous hum (positional, disappears with JV compression), aortopulmonary window, ruptured sinus of Valsalva, coronary AV fistula |
| Treatment | Percutaneous coil/device closure (first-line in adults) if left heart enlargement or prior endarteritis. Surgical ligation: calcified/large/failed transcatheter. Closure contraindicated in Eisenmenger |
| Complications | Infectious endarteritis (0.45%/year even small PDA), PAH/Eisenmenger (~5%), LV failure, differential cyanosis, ductal aneurysm |
| Prevention | Rubella vaccination. Minimize prematurity. Endocarditis prophylaxis NOT routine for small unclosed PDA; required 6 months post-closure |
CATEGORY 2: RIGHT-TO-LEFT SHUNTS (CYANOTIC)
4. TETRALOGY OF FALLOT (TOF)
| Heading | Key Points |
|---|---|
| Etiology | Anterior infundibular septum malalignment → 4 defects: (1) large subaortic VSD, (2) RVOT obstruction, (3) overriding aorta, (4) RVH. 22q11 deletion in ~15%; also Down, CHARGE syndromes. Maternal DM, PKU, retinoic acid |
| Epidemiology | Most common cyanotic CHD in adults. 5-12% of all infant CHD. ~35,000 adults with repaired TOF in the USA |
| Pathophysiology | Unrepaired: RVOT obstruction → R→L shunt through VSD → cyanosis/polycythemia; "tet spells" (RVOT spasm → acute cyanosis). Repaired: pulmonary regurgitation (main residual) → RV dilation → VT/SCD risk |
| Signs & Symptoms | Repaired (common in adults): exercise intolerance, palpitations, syncope. Signs: PR murmur (low diastolic LLSB), RV heave, RBBB on ECG. Unrepaired: cyanosis, clubbing, squatting, tet spells |
| Diagnosis | ECG: RBBB, QRS ≥180 ms = highest SCD risk marker. CXR: "boot-shaped heart" (unrepaired). Cardiac MRI (gold standard): RVEDVI >160 mL/m² → pulmonary valve replacement indicated. Holter: VT burden. Echo: residual anatomy |
| Differential Dx | Other cyanotic CHD (pulmonary atresia + VSD, TGA), ARVC (large RV post-repair), dilated cardiomyopathy |
| Treatment | Pulmonary valve replacement (PVR): surgical or TPVR (Melody/Sapien) for severe PR + RV dilation. ICD: primary prevention if QRS ≥180 ms, inducible VT, severe RV dysfunction. Catheter ablation: IART, VT. Re-operation for RVOT obstruction |
| Complications | Pulmonary regurgitation (nearly universal post-repair), RV failure, sudden cardiac death (VT/VF - 0.5-2%/year), atrial arrhythmias, aortic root dilation, re-operation |
| Prevention | Genetic counseling (22q11). Early definitive repair in infancy. Lifelong MRI surveillance. Timely PVR before irreversible RV dysfunction. ICD for high-risk patients |
5. EISENMENGER SYNDROME
| Heading | Key Points |
|---|---|
| Etiology | Final pathway of large unrepaired L→R shunts: most commonly large VSD, then PDA, ASD (rarer), AVSD. More common in women. Becoming less prevalent with improved early surgical repair |
| Epidemiology | ~1-9 per million population. Young adults (teens to 30s). Female predominance 2:1. Mean survival significantly reduced |
| Pathophysiology | Chronic high-flow, high-pressure → pulmonary vascular remodeling → PVR approaches SVR → shunt reversal (R→L) → systemic cyanosis → secondary erythrocytosis (polycythemia). Paradoxically both thrombotic (hyperviscosity) and bleeding (thrombocytopenia, dysfunctional platelets) |
| Signs & Symptoms | Central cyanosis + clubbing (bilateral; differential cyanosis toes>fingers = Eisenmenger PDA). Dyspnea, chest pain, hemoptysis, palpitations, syncope. Hyperviscosity: headache, blurred vision, fatigue. Signs of RHF. Original shunt murmur disappears; Graham Steell murmur (PR) + TR from PAH |
| Diagnosis | CXR: dilated central PAs, pruned periphery. Echo: R→L shunt, near-systemic RV pressure. Cardiac catheterization (definitive): PVR ≥8 Wood units; vasoreactivity test (failure → inoperable). Labs: polycythemia, thrombocytopenia, high uric acid, iron deficiency possible |
| Differential Dx | Idiopathic PAH (no structural CHD), CTEPH, severe COPD, methemoglobinemia, cyanotic CHD without PAH |
| Treatment | Targeted PAH therapy: Bosentan (FDA-approved for Eisenmenger), sildenafil/tadalafil, prostacyclins. Iron supplementation if deficient. Defect closure contraindicated. Avoid: dehydration, pregnancy, NSAIDs, systemic vasodilators, phlebotomy (unless Hct >65% + symptoms). Heart-lung transplant: last resort |
| Complications | Sudden death, RHF (ultimately fatal), stroke/TIA, brain abscess (R→L bypasses pulmonary filter), hemoptysis, gout, renal dysfunction, pregnancy (30-50% maternal mortality - absolute contraindication) |
| Prevention | Only prevention = timely surgical correction of underlying CHD before PVOD established. Mandatory follow-up of all large CHD lesions. Avoid all precipitating factors once established |
6. EBSTEIN ANOMALY
| Heading | Key Points |
|---|---|
| Etiology | Failure of normal tricuspid valve delamination from RV myocardium. Septal + posterior leaflets are apically displaced; anterior leaflet is large and sail-like. Maternal lithium exposure (1st trimester). Associated: ASD/PFO (~80-90%), WPW (20-25%), pulmonary stenosis |
| Epidemiology | Rare: ~1 per 20,000 births; <1% of CHD. Wide severity spectrum - many mild cases undiagnosed until adulthood |
| Pathophysiology | Apical displacement → "atrialized" RV (thin, non-contractile). TR (poor leaflet coaptation) → massive RA dilation → AF/flutter. R→L shunt through ASD/PFO if RA pressure high → cyanosis. WPW → SVT and risk of SCD |
| Signs & Symptoms | Mild: palpitations, fatigue. Moderate-severe: dyspnea, cyanosis, syncope. Signs: holosystolic TR murmur, loud "sail sound" (large anterior leaflet), right-sided S3/S4, massive cardiomegaly ("box-shaped heart") |
| Diagnosis | ECG: RBBB + giant P waves + delta waves (WPW), prolonged PR. CXR: box-shaped heart, globular cardiomegaly. Echo: apical displacement of septal TV leaflet >8 mm/m²; severity of TR, ASD. MRI: functional RV volume. EP study: accessory pathway mapping |
| Differential Dx | Other causes of right heart enlargement (ASD, idiopathic TR, ARVC), WPW without Ebstein, dilated cardiomyopathy, pericardial effusion |
| Treatment | Tricuspid valve repair (cone reconstruction - preferred) or replacement. ASD/PFO closure at time of surgery. Catheter ablation for WPW (multiple right-sided pathways common). Antiarrhythmics for AF. Bidirectional Glenn for severe RV failure. Heart transplant (end-stage) |
| Complications | Sudden death (WPW → antidromic AF → VF), AF/flutter, paradoxical embolism/stroke, RV failure, progressive cyanosis |
| Prevention | Avoid lithium in 1st trimester when possible. Fetal echocardiography in high-risk pregnancies. Ablate accessory pathways before pregnancy. Regular ACHD specialist follow-up |
CATEGORY 3: OBSTRUCTIVE LESIONS
7. BICUSPID AORTIC VALVE (BAV) / AORTIC STENOSIS
| Heading | Key Points |
|---|---|
| Etiology | NOTCH1 gene mutation; autosomal dominant incomplete penetrance; ~10% first-degree relatives affected. Two cusps fuse (R+L most common, 75%). Associated: coarctation (50-80%), Turner syndrome, Williams syndrome. Calcification accelerated 20-30 years earlier than tricuspid AS |
| Epidemiology | Most common congenital cardiac anomaly (~2% of population). Male:female 3:1 for stenosis. Up to 50% of surgical AS cases in adults. Significant AS/AR develops in ~30-40% by age 60-70 |
| Pathophysiology | Turbulent flow → endothelial injury → calcification → progressive AS (LV pressure overload → concentric LVH → diastolic dysfunction → LV failure). OR poor coaptation → AR (LV volume overload). Intrinsic aortic medial disease → aortopathy independent of valve function → aortic dilation/dissection |
| Signs & Symptoms | Young adult: asymptomatic; systolic ejection click (apex/aortic area; does not vary with respiration). Severe AS classic triad: angina, syncope, dyspnea (on exertion → rest). Signs: harsh late-peaking ejection murmur radiating to carotids, pulsus parvus et tardus, sustained LV apex, soft A2, S4 |
| Diagnosis | ECG: LVH with strain. CXR: dilated ascending aorta, valve calcification. Echo: bicuspid morphology, peak/mean gradient, AVA (<1.0 cm² = severe), LV function, aortic dimensions. CT: calcium scoring (severe if Agatston >2000 AU males, >1200 AU females). Cath: if discordant or pre-CABG |
| Differential Dx | Calcific tricuspid AS (elderly), HOCM (dynamic murmur - Valsalva differentiates), supravalvular/subvalvular AS, aortic sclerosis (no gradient), MR (pansystolic) |
| Treatment | Statins do NOT slow progression. Control hypertension. Intervention for severe symptomatic AS or very severe AS. SAVR (preferred if concomitant aortic surgery needed; Ross procedure for young patients). TAVR (increasingly used in BAV - 2025 ACC/AHA endorsed for appropriate anatomy). Aortic surgery if root >5.0 cm (BAV) |
| Complications | Progressive AS, AR, aortic dissection/aneurysm (intrinsic aortopathy), infective endocarditis, SCD (severe unrepaired AS), LV failure, post-TAVR paravalvular leak/pacemaker need |
| Prevention | Echo screening of 1st-degree relatives. Annual surveillance echo. Strict BP control. Endocarditis prophylaxis (prior IE history). Competitive sports restriction with significant AS or aortic dilation |
8. PULMONARY STENOSIS (PS)
| Heading | Key Points |
|---|---|
| Etiology | Valvular (90%): domed or dysplastic pulmonary valve. Noonan syndrome (commonest genetic cause - dysplastic valve, thick leaflets). Also: Williams, Alagille, congenital rubella (peripheral PS + PDA). Carcinoid syndrome: acquired PS in adults |
| Epidemiology | 3-10% of CHD. Well-tolerated; many survive to adulthood without symptoms. Most severe cases treated in childhood |
| Pathophysiology | RVOT obstruction → RV pressure overload → concentric RVH. Severe: RV failure, TR, RA pressure rise → R→L through PFO/ASD → cyanosis. Post-stenotic PA dilation. Secondary infundibular hypertrophy may worsen obstruction |
| Signs & Symptoms | Mild: asymptomatic, soft murmur. Moderate-severe: fatigue, exertional dyspnea, chest pain, syncope. Signs: systolic ejection click at pulmonary area that decreases on inspiration (distinguishing feature), harsh systolic ejection murmur 2nd LICS (peaks later with severity), wide split S2 with soft P2, RV heave, prominent A-wave in JVP |
| Diagnosis | ECG: right axis deviation, RVH, P pulmonale (severe). CXR: post-stenotic PA dilation, reduced pulmonary vascularity. Echo: domed/dysplastic PV, peak gradient (mild <40, moderate 40-70, severe >70 mmHg), RVH, TR, ASD/PFO |
| Differential Dx | ASD (also split S2 - fixed, not variable), TOF (VSD + overriding aorta), carcinoid (TR + PS in adults with flushing/diarrhea), PAH (loud P2 without murmur) |
| Treatment | Mild (gradient <40 mmHg): observe; excellent prognosis; no intervention. Moderate-severe (>40-50 mmHg or symptomatic): Balloon pulmonary valvuloplasty (BPV) - first-line, excellent results for domed valve. Surgery for dysplastic (Noonan) valves or failed BPV. Monitor for post-BPV pulmonary regurgitation |
| Complications | RV failure (long-term), cyanosis via PFO/ASD, AF (RA dilation), infective endocarditis, post-BPV pulmonary regurgitation (usually mild) |
| Prevention | Rubella vaccination. Neonatal/pediatric screening for early intervention. Genetic testing for Noonan families. Lifelong surveillance post-valvuloplasty |
9. COARCTATION OF THE AORTA
| Heading | Key Points |
|---|---|
| Etiology | Discrete narrowing of descending aorta at/distal to ductus arteriosus (juxtaductal). Associated: BAV (50-80%), Turner syndrome (10-20%), berry aneurysms (~10%), VSD. Two forms: preductal (infantile, severe, presents at birth) vs. postductal (adult, discrete, often missed until adulthood). Male 2:1 |
| Epidemiology | 3-10% of CHD. Most common cause of hypertension in a young adult if undiagnosed. Can present at any age |
| Pathophysiology | Pressure gradient across narrowing: proximal (UE) hypertension (LV overload → LVH → premature CAD, aortic complications) + distal (LE) hypoperfusion (drives collateral artery development - intercostal → internal mammary). Persistent UE HTN post-repair in 50% if repaired after age 40, <10% if repaired age 1-5 |
| Signs & Symptoms | Often asymptomatic; found on BP screening. Headache, epistaxis. Leg fatigue/claudication. Older patients: angina, HF. Signs: BP differential arms>legs (>20 mmHg), weak/absent femoral pulses (radio-femoral delay), bounding brachial pulse, mid-thoracic posterior systolic murmur, systolic ejection click (if associated BAV), corkscrew retinal arteries, bilateral infraclavicular collateral murmurs |
| Diagnosis | ECG: LVH. CXR: "3 sign" (indented aorta between dilated left subclavian above + post-stenotic dilation below), bilateral rib notching (posterior 3rd-8th ribs). Echo: gradient in descending aorta, LVH, BAV. Cardiac MRI (gold standard): anatomy, length, gradient, collaterals, aortic dimensions. CTA: alternative. Cath: pre-intervention hemodynamics |
| Differential Dx | Essential hypertension (no BP differential), renovascular HTN, Takayasu arteritis (diffuse, inflammatory, older females), peripheral artery disease (atherosclerotic risk factors), neurofibromatosis |
| Treatment | Indication: Peak cath gradient ≥20 mmHg with systemic HTN OR significant collateral flow. Transcatheter balloon dilation + stenting (preferred in adults). Surgery (resection + end-to-end, subclavian flap, interposition graft): long-segment, complex, concurrent cardiac lesions. Lifelong MRI/CT surveillance post-repair |
| Complications | Persistent HTN (50% if repaired >40 yrs), re-coarctation, aortic aneurysm at repair site (Dacron patch), aortic dissection (BAV aortopathy), premature CAD, intracranial berry aneurysm rupture (subarachnoid hemorrhage), stroke, LV failure, endocarditis |
| Prevention | Screen all Turner syndrome patients. Screen first-degree relatives. Screen all BAV patients for coarctation. MRA to screen for berry aneurysms in high-risk patients. Strict BP control lifelong post-repair. Restrict competitive sports with significant gradient or dilation |
MASTER QUICK-REFERENCE TABLE
| Defect | Pathophysiology | Cardinal Sign | Best Diagnostic Tool | First-Line Treatment | Key Complication |
|---|---|---|---|---|---|
| ASD | L→R → RV volume overload | Fixed split S2 | Echo ± MRI | Transcatheter closure (Amplatzer) | AF, paradoxical embolism |
| VSD | L→R → LV volume overload | Loud pansystolic murmur LLSB | Echo | Transcatheter/surgical closure | Eisenmenger, AR (outlet VSD) |
| PDA | Continuous aorto-PA shunt | Machinery murmur; differential cyanosis | Echo Doppler | Coil/device closure | Endarteritis, Eisenmenger |
| TOF | RVOT obstruction + VSD R→L | Boot heart / PR murmur (repaired) | Cardiac MRI (RVEDVI) | Pulmonary valve replacement; ICD | Sudden death (QRS >180 ms) |
| Eisenmenger | Fixed PAH; R→L shunt | Central cyanosis + clubbing | Cardiac catheterization (PVR) | Bosentan; avoid closure | Pregnancy (30-50% maternal mortality) |
| Ebstein | Apical TV displacement; TR; WPW | Box-shaped heart; RBBB + delta waves | Echo (TV displacement >8 mm/m²) | TV repair (cone) + accessory pathway ablation | Sudden death (WPW→VF) |
| BAV / AS | LV pressure overload + aortopathy | Ejection click → angina/syncope/dyspnea | Echo (AVA, gradient) + CT calcium | SAVR or TAVR | Aortic dissection |
| Pulmonary Stenosis | RV pressure overload | Pulmonary ejection click (↓ with inspiration); wide soft split S2 | Echo (peak gradient) | Balloon valvuloplasty | RV failure, cyanosis via PFO |
| Coarctation | UE HTN vs. LE hypoperfusion | BP arms>legs; rib notching; "3 sign" | Cardiac MRI | Transcatheter stenting | Persistent HTN, berry aneurysm rupture |
Sources: Goldman-Cecil Medicine Ch. 55; Robbins & Kumar Basic Pathology Ch. 9; Braunwald's Heart Disease; 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline [PMID: 41411480]
This is a shared conversation. Sign in to Orris to start your own chat.